Thiogenesis Therapeutics, Corp. (TTIPF)
US Markets
$0.42
+0.00%
Closing price as of 2026-07-28 · Source: TEK2day Finance
About Thiogenesis Therapeutics, Corp.
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered in Toronto, Canada.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -1.8M | -2.4M | -1.7M | -918K |
| Net Income | -1.9M | -2.4M | -1.7M | -912K |
| Diluted EPS | $-0.04 | $-0.05 | $nan | $-0.02 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.0M | -5.2M | -3.6M | -7.4M |
| Net Income | -3.9M | -5.1M | -3.1M | -7.4M |
| Diluted EPS | $-0.16 | $-0.13 | $-0.07 | $-0.15 |